Pivotal roles of peptide transporter PEPT1 and ATP-binding cassette (ABC) transporter ABCG2 in 5-aminolevulinic acid (ALA)-based photocytotoxicity of gastric cancer cells in vitro

Photodiagnosis and Photodynamic Therapy

Volumn 9, Issue 3, 2012, Pages 204-214

  Hagiya, Yuichiro ^a   Endo, Yoshio ^b   Yonemura, Yutaka ^c   Takahashi, Kiwamu ^d   Ishizuka, Masahiro ^d   Abe, Fuminori ^d   Tanaka, Tohru ^d   Okura, Ichiro ^a   Nakajima, Motowo ^d   Ishikawa, Toshihisa ^e   Ogura, Shun ichiro ^a  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c NPO Organization to Support Peritoneal Dissemination Treatment   (Japan)

^d SBI Pharmaceuticals Co   (Japan)

^e RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

5 Aminolevulinic acid; ABCG2; PEPT1; Photodynamic therapy; Protoporphyrin IX

Indexed keywords

AMINOLEVULINIC ACID; BREAST CANCER RESISTANCE PROTEIN; PEPTIDE TRANSPORTER 1; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; PHOTOCYTOTOXICITY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SPECTROPHOTOMETRY; STOMACH CANCER;

AMINOLEVULINIC ACID; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; NEOPLASM PROTEINS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; STOMACH NEOPLASMS; SYMPORTERS;

EID: 84865966559     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2011.12.004     Document Type: Article

References (51)

1. Dolmans D., Fukumura D., Jain R.K. Photodynamic therapy for cancer. Nat Rev Cancer 2003, 3:380-387.
2. Dougherty T.J., Gomer C.J., Henderson B.W., et al. Photodynamic therapy. J Natl Cancer Inst 1998, 90:889-905.
3. Brown S.B., Brown E.A., Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004, 5:497-508.
4. Krammer B., Plaetzer K. ALA and its clinical impact, from bench to bedside. Photochem Photobiol Sci 2008, 7:283-289.
5. Stummer W., Pichlmeier U., Meinel T., et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006, 7:392-401.
6. Peng Q., Warloe T., Berg K., et al. 5-Aminolevulinic acid-based photodynamic therapy - clinical research and future challenges. Cancer 1997, 79:2282-2308.
7. Ishikawa T. The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci 1992, 17:463-469.
8. Toyoda Y., Hagiya Y., Adachi T., Hoshijima K., Kuo M.T., Ishikawa T. MRP class of human ATP binding cassette (ABC) transporters: historical background and new research directions. Xenobiotica 2008, 38:833-862.
9. Doring F., Walter J., Will J., et al. Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. J Clin Invest 1998, 101:2761-2767.
10. Neumann J., Brandsch M. Delta-aminolevulinic acid transport in cancer cells of the human extrahepatic biliary duct. J Pharmacol Exp Ther 2003, 305:219-224.
11. Novotny A., Xiang J., Stummer W., Teuscher N.S., Smith D.E., Keep R.F. Mechanisms of 5-aminolevulinic acid uptake at the choroid plexus. J Neurochem 2000, 75:321-328.
12. Whitaker C.J., Battah S.H., Forsyth M.J., Edwards C., Boyle R.W., Matthews E.K. Photosensitization of pancreatic tumour cells by delta-aminolaevulinic acid esters. Anticancer Drug Des 2000, 15:161-170.
13. Rodriguez L., Batlle A., Di Venosa G., et al. Study of the mechanisms of uptake of 5-aminolevulinic acid derivatives by PEPT1 and PEPT2 transporters as a tool to improve photodynamic therapy of tumours. Int J Biochem Cell Biol 2006, 38:1530-1539.
14. Jonker J.W., Buitelaar M., Wagenaar E., et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 2002, 99:15649-15654.
15. Zhou S., Zong Y., Ney P.A., Nair G., Stewart C.F., Sorrentino B.P. Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood 2005, 105:2571-2576.
16. Krishnamurthy P., Ross D.D., Nakanishi T., et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004, 279:24218-24225.
17. Tamura A., An R., Hagiya Y., et al. Drug-induced phototoxicity evoked by inhibition of human ABC transporter ABCG2: development of in vitro high-speed screening systems. Expert Opin Drug Metab Toxicol 2008, 4:255-272.
18. Asai T. Establishment and characterization of human undifferentiated carcinoma cell line of the stomach (KKLS), and a trial of a new chemosensitivity test, Liquid Top Layer-MTT Assay (LMA). J Juzen Med Soc 1991, 100:425-444.
19. Tamura A., Onishi Y., An R., et al. In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. Drug Metab Pharmacokinet 2007, 22:428-440.
20. Hagiya Y., Adachi T., Ogura S., et al. Nrf2-dependent induction of human ABC transporter ABCG2 and heme oxygenase-1 in HepG2 cells by photoactivation of porphyrins: biochemical implications for cancer cell response to photodynamic therapy. J Exp Ther Oncol 2008, 7:153-167.
21. Ishikawa T., Nakagawa H., Hagiya Y., Nonoguchi N., Miyatake S., Kuroiwa T. Key role of human ABC transporter ABCG2 in photodynamic therapy and photodynamic diagnosis. Adv Pharmacol Sci 2010, 2010:587306.
22. Adachi T., Nakagawa H., Chung I., et al. Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. J Exp Ther Oncol 2007, 6:335-348.
23. Robey R.W., Steadman K., Polgar O., Bates S.E. ABCG2-mediated transport of photosensitizers - potential impact on photodynamic therapy. Cancer Biol Ther 2005, 4:187-194.
24. Allikmets R., Schriml L.M., Hutchinson A., Romano-Spica V., Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998, 58:5337-5339.
25. Doyle L.A., Yang W.D., Abruzzo L.V., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998, 95:15665-15670.
26. Miyake K., Mickley L., Litman T., et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999, 59:8-13.
27. Saito H., Hirano H., Nakagawa H., et al. A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J Pharmacol Exp Ther 2006, 317:1114-1124.
28. Maliepaard M., van Gastelen M.A., de Jong L.A., et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999, 59:4559-4563.
29. Ross D.D., Yang W., Abruzzo L.V., et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999, 91:429-433.
30. Brangi M., Litman T., Ciotti M., et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999, 59:5938-5946.
31. Patrawala L., Calhoun T., Schneider-Broussard R., Zhou J.J., Claypool K., Tang D.G. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2(+) and ABCG2(-) cancer cells are similarly tumorigenic. Cancer Res 2005, 65:6207-6219.
32. Fei Y.J., Kanai Y., Nussberger S., et al. Expression cloning of a mammalian proton-coupled pligopeptide transporter. Nature 1994, 368:563-566.
33. Shen H., Smith D.E., Yang T.X., Huang Y.N.G., Schnermann J.B., Brosius F.C. Localization of PEPT1 and PEPT2 proton-coupled oligopeptide transporter mRNA and protein in rat kidney. Am J Physiol 1999, 276:F658-F665.
34. Knutter I., Rubio-Aliaga I., Boll M., et al. H+-peptide cotransport in the human bile duct epithelium cell line SK-ChA-1. Am J Physiol Gastrointest Liver Physiol 2002, 283:G222-G229.
35. Inui K., Masuda S., Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int 2000, 58:944-958.
36. Doring F., Will J., Amasheh S., Clauss W., Ahlbrecht H., Daniel H. Minimal molecular determinants of substrates for recognition by the intestinal peptide transporter. J Biol Chem 1998, 273:23211-23218.
37. Becker K.F., Keller G., Hoefler H. The use of molecular biology in diagnosis and prognosis of gastric cancer. Surg Oncol 2000, 9:5-11.
38. Yasui W., Oue N., Ito R., Kuraoka K., Nakayama H. Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci 2004, 95:385-392.
39. Bando E., Yonemura Y., Takeshita Y., et al. Intraoperative lavage for cytological examination in 1297 patients with gastric carcinoma. Am J Surg 1999, 178:256-262.
40. Sugarbaker P.H., Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 2000, 58:96-107.
41. Sadeghi B., Arvieux C., Glehen O., et al. Peritoneal carcinomatosis from non-gynecologic malignancies - results of the EVOCAPE 1 multicentric prospective study. Cancer 2000, 88:358-363.
42. Chu D.Z.J., Lang N.P., Thompson C., Osteen P.K., Westbrook K.C. Peritoneal carcinomatosis in nongynecologic malignancy - a prospective-study of prognostic factors. Cancer 1989, 63:364-367.
43. Ellis D.A., William E.H., Patrick N. Pediatric nephrology 2003, Lippincott Williams & Wilkins, Philadelphia, PA. 5th ed.
44. Stummer W., Reulen H.J., Novotny A., Stepp H., Tonn J.C. Fluorescence-guided resections of malignant gliomas--an overview. Acta Neurochir Suppl 2003, 88:9-12.
45. Valdes P.A., Samkoe K., O'Hara J.A., Roberts D.W., Paulsen K.D., Pogue B.W. Deferoxamine iron chelation increases delta-aminolevulinic acid induced protoporphyrin IX in xenograft glioma model. Photochem Photobiol 2010, 86:471-475.
46. Yang J.B., Xia Y.M., Liu X.M., Jiang S., Xiong L.Y. Desferrioxamine shows different potentials for enhancing 5-aminolaevulinic acid-based photodynamic therapy in several cutaneous cell lines. Lasers Med Sci 2010, 25:251-257.
47. Roberts D.W., Valdes P.A., Harris B.T., et al. Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between delta-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. J Neurosurg 2011, 114:595-603.
48. Claydon P.E., Ackroyd R. 5-Aminolaevulinic acid-induced photodynamic therapy and photodetection in Barrett's esophagus. Dis Esophagus 2004, 17:205-212.
49. Wilby D., Thomas K., Ray E., Chappell B., O'Brien T. Bladder cancer: new TUR techniques. World J Urol 2009, 27:309-312.
50. Collinet P., Delemer M., Jouve E., et al. Fluorescence diagnosis of cervical squamous intraepithelial lesions: a clinical feasability study. Photodiagn Photodyn Ther 2007, 4:112-116.
51. Braathen L.R., Szeimies R.M., Basset-Seguin N., et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol US 2007, 56:125-143.